Clinical Trial Update: The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAART [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Ampligen as part of a strategic therapeutic intervention with HAART for HIV infection and HIV seropositivity has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• HIV Seropositivity

Drugs mentioned

• Ampligen (rintatolimod)

Snippet

Sponsor: AIM ImmunoTech Inc. | Conditions: HIV Seropositivity, HIV Infection | Phase 2 | Status: COMPLETED